KDIGO 2024 CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS

The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis represents a focused update of the ANCA-Associated Vasculitis chapter from the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. The aim is to assist clinicians caring for people with ANCA-associated vasculitis. The update takes into consideration evidence from randomized controlled trials published since February 2022. As in 2021, the chapter follows the same template providing guidance related to diagnosis, prognosis, treatment, and special situations. Based on the evidence, this update is mostly focused on guidance related to treatment of ANCA-associated vasculitis. Development of this guideline followed an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the certainty of the evidence and the strength of recommendations followed the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach. Limitations of the evidence are discussed and areas of future research are also presented.